stockrow10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) Revenue
10x Genomics's revenue for fiscal 2025 was $642.8M, up 5.25% from $610.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was $618.6M. Over the past ten years it has ranged from $71.1M (fiscal 2017) to $642.8M (fiscal 2025) — the current reading is the highest in ten years. 10x Genomics ranks 38th of 140 Medical Devices companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $642.8M | 5.25% |
| FY2024 | $610.8M | (1.28%) |
| FY2023 | $618.7M | 19.81% |
| FY2022 | $516.4M | 5.28% |
| FY2021 | $490.5M | 64.13% |
| FY2020 | $298.8M | 21.53% |
| FY2019 | $245.9M | 68.06% |
| FY2018 | $146.3M | 105.83% |
| FY2017 | $71.1M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $150.7M | (0.24%) |
| Jun 2026 | $151.0M | 0.13% |
| Mar 2026 | $150.8M | (9.15%) |
| Dec 2025 | $166.0M | 11.43% |
| 27 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $10.5B |
| BRKR Bruker Corporation compare | $3.5B |
| PODD Insulet Corporation compare | $3.2B |
| GMED Globus Medical, Inc. compare | $3.1B |
| BIO.B Bio-Rad Laboratories, Inc. compare | $2.6B |
| BIO Bio-Rad Laboratories, Inc. compare | $2.6B |
| PEN Penumbra, Inc. compare | $1.6B |
| HAE Haemonetics Corporation compare | $1.4B |
| TXG 10x Genomics | $616.9M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TXG
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement